Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer (METRO)
Sponsor: Alesund Hospital
Listed as NCT04983095, this NA trial focuses on Positron-Emission Tomography and Prostate Cancer Metastatic and remains actively recruiting participants. Sponsored by Alesund Hospital, it has been updated 9 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Recruiting NA
-
Mar 2025 — Feb 2026 [monthly]
Recruiting NA
-
Feb 2025 — Mar 2025 [monthly]
Recruiting NA
-
Dec 2024 — Feb 2025 [monthly]
Recruiting NA
Phase: PHASE3 → NA
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jan 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Jun 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alesund Hospital
- Capio Sankt Görans Hospital
- Karin Soderkvist
- Karolinska University Hospital
- Region Skane
- Region Örebro County
- Ryhov County Hospital
- Sahlgrenska University Hospital
- Stockholm South General Hospital
- Trondheim University Hospital
- University Hospital, Umeå
For direct contact, visit the study record on ClinicalTrials.gov .